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Are	 ﾠpracticing	 ﾠmedical	 ﾠdoctors	 ﾠup	 ﾠto	 ﾠdate	 ﾠon	 ﾠthe	 ﾠlatest	 ﾠ
advances	 ﾠin	 ﾠtheir	 ﾠfield?	 ﾠIs	 ﾠpublished	 ﾠresearch	 ﾠvalid	 ﾠand	 ﾠ
reliable?	 ﾠWhy	 ﾠare	 ﾠdoctors	 ﾠseldom	 ﾠinvolved	 ﾠin	 ﾠresearch?	 ﾠ
The	 ﾠ aim	 ﾠ of	 ﾠ this	 ﾠ editorial	 ﾠ is	 ﾠ to	 ﾠ explore	 ﾠ some	 ﾠ of	 ﾠ these	 ﾠ
complex	 ﾠissues.	 ﾠ
	 ﾠ
Prescribing	 ﾠhabits	 ﾠand	 ﾠtherapeutic	 ﾠadvance	 ﾠ
Patients	 ﾠ may	 ﾠb e l i e v e 	 ﾠt h a t 	 ﾠt h e i r 	 ﾠd o c t o r 	 ﾠi s 	 ﾠa	 ﾠs o u r c e 	 ﾠo f 	 ﾠ
impartial	 ﾠand	 ﾠup	 ﾠto	 ﾠdate	 ﾠinformation	 ﾠin	 ﾠhis	 ﾠor	 ﾠher	 ﾠfield	 ﾠ
but	 ﾠhow	 ﾠdo	 ﾠdoctors	 ﾠkeep	 ﾠup	 ﾠto	 ﾠdate?	 ﾠGabbay	 ﾠand	 ﾠLe	 ﾠ
May	 ﾠreported	 ﾠthe	 ﾠfollowing:	 ﾠ
	 ﾠ
‘…clinicians	 ﾠrarely	 ﾠaccessed,	 ﾠappraised,	 ﾠand	 ﾠused	 ﾠexplicit	 ﾠ
evidence	 ﾠdirectly	 ﾠfrom	 ﾠresearch	 ﾠor	 ﾠother	 ﾠformal	 ﾠsources;	 ﾠ
rare	 ﾠ exceptions	 ﾠ were	 ﾠ where	 ﾠ they	 ﾠ might	 ﾠ consult	 ﾠ such	 ﾠ
sources	 ﾠafter	 ﾠdealing	 ﾠwith	 ﾠa	 ﾠcase	 ﾠthat	 ﾠhad	 ﾠparticularly	 ﾠ
challenged	 ﾠthem.	 ﾠInstead,	 ﾠthey	 ﾠrelied	 ﾠon	 ﾠwhat	 ﾠwe	 ﾠhave	 ﾠ
called	 ﾠ “mindlines,”	 ﾠ collectively	 ﾠ reinforced,	 ﾠ internalised	 ﾠ
tacit	 ﾠguidelines,	 ﾠwhich	 ﾠwere	 ﾠinformed	 ﾠby	 ﾠbrief	 ﾠreading,	 ﾠ
but	 ﾠmainly	 ﾠby	 ﾠtheir	 ﾠinteractions	 ﾠwith	 ﾠeach	 ﾠother…opinion	 ﾠ
leaders,	 ﾠ patients…pharmaceutical	 ﾠ representatives	 ﾠ and	 ﾠ
by	 ﾠother	 ﾠsources	 ﾠof	 ﾠlargely	 ﾠtacit	 ﾠknowledge	 ﾠthat	 ﾠbuilt	 ﾠon	 ﾠ
their	 ﾠearly	 ﾠtraining	 ﾠand	 ﾠtheir	 ﾠown	 ﾠand	 ﾠtheir	 ﾠcolleagues'	 ﾠ
experience’.
1	 ﾠ
	 ﾠ
Are	 ﾠdoctors	 ﾠwho	 ﾠprescribe	 ﾠthe	 ﾠlatest	 ﾠdrugs	 ﾠmore	 ﾠlikely	 ﾠto	 ﾠ
be	 ﾠup	 ﾠto	 ﾠdate?	 ﾠGeneral	 ﾠpractitioners	 ﾠfor	 ﾠexample	 ﾠhave	 ﾠ
been	 ﾠfound	 ﾠto	 ﾠbe	 ﾠreactive	 ﾠand	 ﾠopportunistic	 ﾠrecipients	 ﾠ
of	 ﾠnew	 ﾠdrug	 ﾠinformation,	 ﾠand	 ﾠrarely	 ﾠreport	 ﾠundertaking	 ﾠ
an	 ﾠactive	 ﾠinformation	 ﾠsearch.	 ﾠThe	 ﾠdecision	 ﾠto	 ﾠinitiate	 ﾠ
a	 ﾠ new	 ﾠ drug	 ﾠ is	 ﾠ heavily	 ﾠ influenced	 ﾠ by	 ﾠ advertising,	 ﾠ
endorsement	 ﾠ by	 ﾠ colleagues	 ﾠ and	 ﾠ hospital	 ﾠ
consultants.
2	 ﾠ Furthermore	 ﾠ new	 ﾠ medications	 ﾠ offer	 ﾠ
little,	 ﾠ if	 ﾠ any,	 ﾠ incremental	 ﾠ value	 ﾠ over	 ﾠ existing	 ﾠ
therapies.	 ﾠ The	 ﾠ combination	 ﾠ of	 ﾠ inadequate	 ﾠ
information	 ﾠabout	 ﾠthe	 ﾠpotential	 ﾠside	 ﾠeffects	 ﾠof	 ﾠnew	 ﾠ
drugs	 ﾠplus	 ﾠtheir	 ﾠlimited	 ﾠvalue	 ﾠstrongly	 ﾠargues	 ﾠagainst	 ﾠ
their	 ﾠearly	 ﾠuse	 ﾠexcept	 ﾠin	 ﾠexceptional	 ﾠcircumstances.
3	 ﾠ	 ﾠ
	 ﾠ
It	 ﾠis	 ﾠtelling	 ﾠthat	 ﾠdrug	 ﾠcompanies	 ﾠare	 ﾠspending	 ﾠbillions	 ﾠ
every	 ﾠ year	 ﾠ promoting	 ﾠ their	 ﾠ products.
4	 ﾠI t 	 ﾠi s 	 ﾠa l s o 	 ﾠ
notable	 ﾠthat	 ﾠmany	 ﾠnew	 ﾠdrugs	 ﾠare	 ﾠwithdrawn	 ﾠwithin	 ﾠ
a	 ﾠvery	 ﾠshort	 ﾠtime	 ﾠof	 ﾠtheir	 ﾠlaunch.
5	 ﾠWorryingly,	 ﾠthere	 ﾠ
is	 ﾠsometimes	 ﾠa	 ﾠrelative	 ﾠlack	 ﾠof	 ﾠurgency	 ﾠwhen	 ﾠa	 ﾠdrug	 ﾠ
is	 ﾠclearly	 ﾠshown	 ﾠto	 ﾠbe	 ﾠharming	 ﾠpatients.	 ﾠFor	 ﾠexample	 ﾠ
19.8	 ﾠ million	 ﾠ patients	 ﾠ were	 ﾠ prescribed	 ﾠ five	 ﾠ
questionable	 ﾠd r u g s 	 ﾠb e f o r e
	 ﾠ action	 ﾠ was	 ﾠ taken	 ﾠ to	 ﾠ
remove	 ﾠ them	 ﾠ from	 ﾠ the	 ﾠ market.	 ﾠT h i s 	 ﾠi n c l u d e d 	 ﾠ
painkillers,	 ﾠ anti-ﾭ‐histamines,	 ﾠ drugs	 ﾠ used	 ﾠ to	 ﾠ treat	 ﾠ
obesity	 ﾠ and	 ﾠ anti-ﾭ‐hypertensive	 ﾠ drugs.
5	 ﾠN o t	 ﾠ one	 ﾠ of	 ﾠ
these	 ﾠwere	 ﾠlifesaving	 ﾠnor,	 ﾠin	 ﾠmany	 ﾠcases,	 ﾠwere	 ﾠthey	 ﾠ
the
	 ﾠ only	 ﾠ drugs	 ﾠ available	 ﾠ for	 ﾠ that	 ﾠ indication.	 ﾠ In	 ﾠ
another	 ﾠcase	 ﾠphysicians	 ﾠprescribed	 ﾠa	 ﾠnew	 ﾠpainkiller	 ﾠ
to	 ﾠ2.5	 ﾠmillion	 ﾠpatients	 ﾠwith	 ﾠacute	 ﾠpain,	 ﾠeven
	 ﾠthough	 ﾠ
many	 ﾠwell-ﾭ‐tested	 ﾠ similar	 ﾠ drugs	 ﾠ were	 ﾠ available	 ﾠa n d 	 ﾠ
the	 ﾠ drug	 ﾠ was	 ﾠ known	 ﾠ to	 ﾠ elevate	 ﾠ liver	 ﾠ enzymes.	 ﾠ
Similarly	 ﾠthe	 ﾠrationale	 ﾠfor	 ﾠnot	 ﾠwithdrawing	 ﾠan	 ﾠanti-ﾭ‐
histamine
	 ﾠfrom	 ﾠthe	 ﾠmarket	 ﾠas	 ﾠsoon	 ﾠas	 ﾠresearchers	 ﾠ
clearly	 ﾠidentified	 ﾠit
	 ﾠas	 ﾠcausing	 ﾠdeaths	 ﾠhas	 ﾠnot	 ﾠbeen	 ﾠ
explained.
6	 ﾠI t 	 ﾠi s 	 ﾠs u r p r i s i n g
	 ﾠ that	 ﾠ the	 ﾠ drug	 ﾠ was	 ﾠ not	 ﾠ
removed	 ﾠfrom	 ﾠthe	 ﾠmarket	 ﾠwhen	 ﾠthe	 ﾠadverse
	 ﾠeffects	 ﾠ
were	 ﾠidentified,	 ﾠbut	 ﾠonly	 ﾠafter	 ﾠthe	 ﾠmanufacturer	 ﾠhad	 ﾠ
developed
	 ﾠa	 ﾠnew	 ﾠproduct	 ﾠto	 ﾠsubstitute	 ﾠfor	 ﾠit.	 ﾠ	 ﾠ
	 ﾠ
For	 ﾠ some	 ﾠ relatively	 ﾠ rare	 ﾠc o n d i t i o n s 	 ﾠp r a c t i c i n g 	 ﾠ
doctors	 ﾠmay	 ﾠknow	 ﾠlittle	 ﾠmore	 ﾠthan	 ﾠthey	 ﾠknew	 ﾠwhen	 ﾠ
they	 ﾠ first	 ﾠ qualified.
7	 ﾠ Physicians	 ﾠ who	 ﾠ have	 ﾠ been	 ﾠ in	 ﾠ
practice	 ﾠfor	 ﾠa	 ﾠlong	 ﾠtime	 ﾠmay	 ﾠbe	 ﾠat	 ﾠgreatest	 ﾠrisk	 ﾠof	 ﾠ
being	 ﾠ out	 ﾠ of	 ﾠ date	 ﾠ in	 ﾠ their	 ﾠ recommendations	 ﾠ and	 ﾠ
practice.	 ﾠ Therefore,	 ﾠ this	 ﾠ group	 ﾠ of	 ﾠ physicians	 ﾠ may	 ﾠ
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 ﾠ
need	 ﾠ support	 ﾠ to	 ﾠ be	 ﾠ kept	 ﾠ abreast	 ﾠ of	 ﾠ research.
8	 ﾠO l d e r 	 ﾠ
physicians	 ﾠalso	 ﾠseem	 ﾠless	 ﾠlikely	 ﾠto	 ﾠadopt	 ﾠnewly	 ﾠproven	 ﾠ
therapies	 ﾠand	 ﾠmay	 ﾠbe	 ﾠless	 ﾠreceptive	 ﾠto	 ﾠnew	 ﾠstandards	 ﾠof	 ﾠ
care.
9-ﾭ‐10	 ﾠSo	 ﾠwhat	 ﾠis	 ﾠthe	 ﾠrole	 ﾠof	 ﾠso-ﾭ‐called	 ﾠpeer	 ﾠreviewed	 ﾠ
publication?	 ﾠ
	 ﾠ
Publication	 ﾠand	 ﾠmedical	 ﾠscience	 ﾠ
It	 ﾠis	 ﾠestimated	 ﾠthat	 ﾠthere	 ﾠare	 ﾠ1.29	 ﾠpapers	 ﾠpublished	 ﾠin	 ﾠ
the	 ﾠ peer	 ﾠ reviewed	 ﾠ medical	 ﾠ literature	 ﾠ every	 ﾠ minute.
11	 ﾠ
Even	 ﾠif	 ﾠa	 ﾠdoctor	 ﾠwere	 ﾠable	 ﾠto	 ﾠkeep	 ﾠup	 ﾠwith	 ﾠthis	 ﾠvolume	 ﾠ
of	 ﾠreading,	 ﾠit	 ﾠis	 ﾠsaid	 ﾠthat	 ﾠmuch	 ﾠof	 ﾠwhat	 ﾠis	 ﾠpublished	 ﾠis	 ﾠ
flawed.	 ﾠ Richard	 ﾠ Smith,	 ﾠ former	 ﾠe d i t o r 	 ﾠo f 	 ﾠt h e 	 ﾠBritish	 ﾠ
Medical	 ﾠJournal	 ﾠ(BMJ),	 ﾠis	 ﾠquoted	 ﾠas	 ﾠsaying	 ﾠthat	 ﾠonly	 ﾠ5%	 ﾠ
of	 ﾠ published	 ﾠ papers	 ﾠ reached	 ﾠ minimum	 ﾠ standards	 ﾠ of	 ﾠ
scientific	 ﾠsoundness	 ﾠand	 ﾠclinical	 ﾠrelevance,	 ﾠand	 ﾠin	 ﾠmost	 ﾠ
journals	 ﾠthe	 ﾠfigure	 ﾠwas	 ﾠless	 ﾠthan	 ﾠ1%.
12	 ﾠ
	 ﾠ
In	 ﾠthe	 ﾠperiod	 ﾠfrom	 ﾠ2000–2010	 ﾠa	 ﾠtotal	 ﾠof	 ﾠ788	 ﾠpapers	 ﾠhave	 ﾠ
been	 ﾠretracted,	 ﾠi.e.	 ﾠexpunged	 ﾠfrom	 ﾠthe	 ﾠpublic	 ﾠrecord.
13	 ﾠ
Approximately	 ﾠthree-ﾭ‐quarters	 ﾠof	 ﾠthese	 ﾠpapers	 ﾠhad	 ﾠbeen	 ﾠ
withdrawn	 ﾠbecause	 ﾠof	 ﾠa	 ﾠserious	 ﾠerror;	 ﾠthe	 ﾠrest	 ﾠof	 ﾠthe	 ﾠ
retractions	 ﾠwere	 ﾠattributed	 ﾠto	 ﾠfraud	 ﾠ(data	 ﾠfabrication	 ﾠor	 ﾠ
falsification).	 ﾠ The	 ﾠ fakes	 ﾠ were	 ﾠ more	 ﾠ likely	 ﾠ to	 ﾠ appear	 ﾠ in	 ﾠ
leading	 ﾠ publications	 ﾠ with	 ﾠ a	 ﾠ high	 ﾠ "impact	 ﾠ factor".	 ﾠT h e 	 ﾠ
impact	 ﾠfactor	 ﾠis	 ﾠa	 ﾠproxy	 ﾠmeasure	 ﾠof	 ﾠhow	 ﾠoften	 ﾠresearch	 ﾠ
is	 ﾠcited	 ﾠin	 ﾠother	 ﾠpeer	 ﾠreviewed	 ﾠjournals.	 ﾠMore	 ﾠthan	 ﾠhalf	 ﾠ
(53%)	 ﾠof	 ﾠthe	 ﾠfaked	 ﾠresearch	 ﾠpapers	 ﾠhad	 ﾠbeen	 ﾠwritten	 ﾠby	 ﾠ
a	 ﾠfirst	 ﾠauthor	 ﾠwho	 ﾠwas	 ﾠa	 ﾠ"repeat	 ﾠoffender".	 ﾠThis	 ﾠwas	 ﾠthe	 ﾠ
case	 ﾠin	 ﾠonly	 ﾠone	 ﾠin	 ﾠfive	 ﾠ(18%)	 ﾠof	 ﾠthe	 ﾠerroneous	 ﾠpapers.
13	 ﾠ
At	 ﾠ about	 ﾠ the	 ﾠ same	 ﾠ time	 ﾠ it	 ﾠ was	 ﾠ estimated	 ﾠt h a t 	 ﾠt h e 	 ﾠ
number	 ﾠof	 ﾠarticles	 ﾠpublished	 ﾠbetween	 ﾠ1950	 ﾠand	 ﾠ2004	 ﾠ
that	 ﾠought	 ﾠto	 ﾠbe	 ﾠretracted	 ﾠshould	 ﾠhave	 ﾠbeen	 ﾠas	 ﾠmany	 ﾠas	 ﾠ
100,000	 ﾠ and	 ﾠ at	 ﾠ least	 ﾠ 10,000.
14	 ﾠT h e 	 ﾠa u t h o r s 	 ﾠf u r t h e r 	 ﾠ
conclude	 ﾠ that	 ﾠ although	 ﾠ high	 ﾠ impact	 ﾠ journals	 ﾠ tend	 ﾠ to	 ﾠ
have	 ﾠfewer	 ﾠundetected	 ﾠflawed	 ﾠarticles	 ﾠthan	 ﾠtheir	 ﾠlower-ﾭ‐
impact	 ﾠpeers,	 ﾠeven	 ﾠthe	 ﾠmost	 ﾠvigilant	 ﾠjournals	 ﾠpotentially	 ﾠ
host	 ﾠpapers	 ﾠthat	 ﾠshould	 ﾠbe	 ﾠretracted.
14	 ﾠ
	 ﾠ
Retraction	 ﾠor	 ﾠnot,	 ﾠone	 ﾠwould	 ﾠlike	 ﾠto	 ﾠthink	 ﾠthat	 ﾠdoctors	 ﾠ
are	 ﾠ able	 ﾠ to	 ﾠ spot	 ﾠ flawed	 ﾠ papers	 ﾠ and,	 ﾠb e t t e r 	 ﾠs t i l l ,	 ﾠ are	 ﾠ
unlikely	 ﾠ to	 ﾠ have	 ﾠ their	 ﾠ clinical	 ﾠ practice	 ﾠ misled	 ﾠ by	 ﾠ poor	 ﾠ
science	 ﾠ or	 ﾠ glossy	 ﾠ leaflets	 ﾠ for	 ﾠ new	 ﾠ and	 ﾠ untested	 ﾠ
treatments.	 ﾠ Let	 ﾠ us	 ﾠ start	 ﾠ with	 ﾠ the	 ﾠ first	 ﾠ question:	 ﾠd o 	 ﾠ
doctors	 ﾠread	 ﾠresearch	 ﾠpapers?	 ﾠHere	 ﾠis	 ﾠa	 ﾠquote	 ﾠfrom	 ﾠa	 ﾠ
doctor	 ﾠwriting	 ﾠin	 ﾠthe	 ﾠBMJ:	 ﾠ
	 ﾠ
‘The	 ﾠvolume	 ﾠof	 ﾠstatistical	 ﾠargument	 ﾠ[in	 ﾠresearch	 ﾠpapers]	 ﾠ
also	 ﾠseems	 ﾠpart	 ﾠof	 ﾠthe	 ﾠsame	 ﾠdisingenuous	 ﾠprocess.	 ﾠHow	 ﾠ
many	 ﾠdoctors	 ﾠhave	 ﾠa	 ﾠclue	 ﾠwhat	 ﾠit	 ﾠmeans?	 ﾠOf	 ﾠall	 ﾠthe	 ﾠ
areas	 ﾠ of	 ﾠ mathematics,	 ﾠ probability,	 ﾠ and	 ﾠ its	 ﾠ
inscrutable	 ﾠdaughter	 ﾠstatistics,	 ﾠare	 ﾠthe	 ﾠmost	 ﾠslippery	 ﾠ
to	 ﾠgrasp.	 ﾠYet	 ﾠauthors	 ﾠroutinely	 ﾠdrop	 ﾠlarge	 ﾠchunks	 ﾠof	 ﾠ
this	 ﾠ extremely	 ﾠ difficult	 ﾠ stuff	 ﾠ into	 ﾠ papers	 ﾠ that	 ﾠ are	 ﾠ
supposed	 ﾠ to	 ﾠ be	 ﾠ there	 ﾠ to	 ﾠ illuminate	 ﾠ practice	 ﾠ for	 ﾠ
doctors.	 ﾠ But	 ﾠ most	 ﾠ doctors,	 ﾠ including	 ﾠ myself,	 ﾠ don't	 ﾠ
understand	 ﾠit’.
15	 ﾠ
	 ﾠ
What	 ﾠis	 ﾠthe	 ﾠpoint	 ﾠof	 ﾠpublishing	 ﾠresearch	 ﾠpapers	 ﾠthat	 ﾠ
cannot	 ﾠ be	 ﾠ absorbed	 ﾠ by	 ﾠ the	 ﾠ target	 ﾠ audience?	 ﾠ One	 ﾠ
author	 ﾠsuggested	 ﾠa	 ﾠpossible	 ﾠanswer:	 ﾠ	 ﾠ
‘Authors	 ﾠare	 ﾠeager	 ﾠto	 ﾠget	 ﾠtheir	 ﾠnames	 ﾠin	 ﾠprint	 ﾠnot	 ﾠ
because	 ﾠthey	 ﾠare	 ﾠbursting	 ﾠto	 ﾠtell	 ﾠus	 ﾠsomething	 ﾠbut	 ﾠ
for	 ﾠ more	 ﾠ solemn	 ﾠ reasons.	 ﾠ Another	 ﾠ paper	 ﾠ means	 ﾠ
another	 ﾠ line	 ﾠ on	 ﾠ a	 ﾠ curriculum	 ﾠ vitae,	 ﾠ another	 ﾠ step	 ﾠ
towards	 ﾠa	 ﾠjob	 ﾠor	 ﾠa	 ﾠresearch	 ﾠgrant.’	 ﾠ
16	 ﾠ
Publishers	 ﾠand	 ﾠmedical	 ﾠscience	 ﾠ
Journals	 ﾠrely	 ﾠon	 ﾠ‘peers’	 ﾠto	 ﾠdecide	 ﾠwhich	 ﾠpapers	 ﾠmerit	 ﾠ
publication	 ﾠ and	 ﾠ which	 ﾠ should	 ﾠ be	 ﾠ jettisoned.	 ﾠ The	 ﾠ
process	 ﾠof	 ﾠpeer	 ﾠreview	 ﾠis	 ﾠrecognised	 ﾠto	 ﾠbe	 ﾠflawed.
17	 ﾠ
The	 ﾠ quality	 ﾠ of	 ﾠ the	 ﾠ reviews	 ﾠv a r i e s . 	 ﾠT h e r e 	 ﾠm a y 	 ﾠb e 	 ﾠ
divergent	 ﾠ views	 ﾠ expressed	 ﾠ in	 ﾠ the	 ﾠ review	 ﾠ and	 ﾠ it	 ﾠ is	 ﾠ
sometimes	 ﾠ difficult	 ﾠ to	 ﾠ determine	 ﾠ why	 ﾠ an	 ﾠ editor	 ﾠ
rejects	 ﾠ or	 ﾠ indeed	 ﾠ accepts	 ﾠ a	 ﾠ submission	 ﾠ without	 ﾠ
concluding	 ﾠ that	 ﾠ the	 ﾠ editor’s	 ﾠ biases	 ﾠ have	 ﾠ played	 ﾠ a	 ﾠ
significant	 ﾠ role	 ﾠ in	 ﾠ that	 ﾠ decision.	 ﾠ In	 ﾠ many	 ﾠ cases,	 ﾠ
especially	 ﾠin	 ﾠniche	 ﾠareas	 ﾠa	 ﾠcompetitor	 ﾠwho	 ﾠmay	 ﾠor	 ﾠ
may	 ﾠnot	 ﾠdeclare	 ﾠa	 ﾠconflict	 ﾠof	 ﾠinterest	 ﾠmay	 ﾠ	 ﾠbe	 ﾠinvited	 ﾠ
to	 ﾠreview	 ﾠthe	 ﾠpaper.	 ﾠ	 ﾠIf	 ﾠthe	 ﾠidentity	 ﾠof	 ﾠthe	 ﾠreviewer	 ﾠis	 ﾠ
kept	 ﾠ from	 ﾠ the	 ﾠ authors,	 ﾠ the	 ﾠ reviewer	 ﾠ is	 ﾠ free	 ﾠ to	 ﾠ
recommend	 ﾠrejection	 ﾠor	 ﾠpublication	 ﾠwithout	 ﾠfear	 ﾠof	 ﾠ
recrimination	 ﾠ in	 ﾠ what	 ﾠ is	 ﾠ known	 ﾠ as	 ﾠ “blind”	 ﾠ peer	 ﾠ
review.	 ﾠ In	 ﾠ very	 ﾠ specialised	 ﾠ topics	 ﾠ the	 ﾠ identity	 ﾠ of	 ﾠ
authors	 ﾠcan	 ﾠbe	 ﾠvery	 ﾠhard	 ﾠto	 ﾠconceal	 ﾠfrom	 ﾠan	 ﾠexpert	 ﾠ
in	 ﾠthe	 ﾠfield	 ﾠat	 ﾠthe	 ﾠtime	 ﾠof	 ﾠreview.
	 ﾠSecondly	 ﾠpublishing	 ﾠ
is	 ﾠa	 ﾠpowerful,	 ﾠprestigious	 ﾠand	 ﾠlucrative	 ﾠbusiness.	 ﾠNo	 ﾠ
journal	 ﾠyet	 ﾠhas	 ﾠtaken	 ﾠup	 ﾠa	 ﾠlong-ﾭ‐standing	 ﾠsuggestion	 ﾠ
to	 ﾠ remove	 ﾠ the	 ﾠ names	 ﾠ of	 ﾠ authors	 ﾠ from	 ﾠ published	 ﾠ
papers.	 ﾠThis	 ﾠwould	 ﾠensure	 ﾠthat	 ﾠ	 ﾠpapers	 ﾠare	 ﾠpublished	 ﾠ
only	 ﾠ for	 ﾠ the	 ﾠ sake	 ﾠ of	 ﾠ disseminating	 ﾠ information.	 ﾠ
However	 ﾠt o 	 ﾠd o 	 ﾠs o 	 ﾠw o u l d 	 ﾠb e 	 ﾠt o 	 ﾠm a k e 	 ﾠt h e 	 ﾠj o urnal	 ﾠ
much	 ﾠ less	 ﾠ attractive	 ﾠ to	 ﾠ authors	 ﾠ and	 ﾠ therefore	 ﾠ
advertisers	 ﾠand	 ﾠother	 ﾠcash	 ﾠcows.
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To	 ﾠfully	 ﾠappreciate	 ﾠthe	 ﾠvalue	 ﾠof	 ﾠjournal	 ﾠarticles	 ﾠto	 ﾠtheir	 ﾠ
target	 ﾠ audience,	 ﾠ namely	 ﾠ university	 ﾠ researchers,	 ﾠa n d 	 ﾠ
their	 ﾠhost	 ﾠinstitutions	 ﾠone	 ﾠmight	 ﾠconsider	 ﾠthe	 ﾠvalue	 ﾠof	 ﾠa	 ﾠ
paper	 ﾠ in	 ﾠ a	 ﾠ highly-ﾭ‐rated	 ﾠ journal	 ﾠ (impact	 ﾠ factor	 ﾠ >40)	 ﾠ
compared	 ﾠto	 ﾠone	 ﾠin	 ﾠa	 ﾠmore	 ﾠmodestly	 ﾠrated	 ﾠone	 ﾠ(impact	 ﾠ
factor	 ﾠ<2).	 ﾠA	 ﾠpaper	 ﾠin	 ﾠthe	 ﾠhigh	 ﾠimpact	 ﾠjournal	 ﾠmay	 ﾠhave	 ﾠ
an	 ﾠ Eigenfactor	 ﾠs c o r e 	 ﾠo f 	 ﾠ0 . 6 7 . 	 ﾠT h e 	 ﾠEigenfactor	 ﾠs core	 ﾠ
calculation	 ﾠis	 ﾠbased	 ﾠon	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠtimes	 ﾠarticles	 ﾠfrom	 ﾠ
the	 ﾠjournal	 ﾠpublished	 ﾠin	 ﾠthe	 ﾠpast	 ﾠfive	 ﾠyears	 ﾠhave	 ﾠbeen	 ﾠ
cited	 ﾠin	 ﾠthe	 ﾠyear.
19	 ﾠA	 ﾠpaper	 ﾠpublished	 ﾠin	 ﾠa	 ﾠ‘lesser’	 ﾠjournal	 ﾠ
has	 ﾠa	 ﾠEigenfactor	 ﾠscore	 ﾠof	 ﾠ0.003.	 ﾠNaturally	 ﾠa	 ﾠuniversity	 ﾠ
dean	 ﾠ would	 ﾠ be	 ﾠ impressed	 ﾠ with	 ﾠ work	 ﾠ cited	 ﾠ frequently	 ﾠ
rather	 ﾠthan	 ﾠseldom.	 ﾠBut	 ﾠwhat	 ﾠis	 ﾠeven	 ﾠmore	 ﾠlikely	 ﾠis	 ﾠthat	 ﾠ
the	 ﾠacademic	 ﾠwith	 ﾠthe	 ﾠpaper	 ﾠin	 ﾠa	 ﾠso-ﾭ‐called	 ﾠhigh	 ﾠimpact	 ﾠ
journal	 ﾠ will	 ﾠ be	 ﾠ more	 ﾠ likely	 ﾠ to	 ﾠ be	 ﾠ successful	 ﾠ on	 ﾠ grant	 ﾠ
applications	 ﾠ and	 ﾠ be	 ﾠ invited	 ﾠ to	 ﾠ speak	 ﾠ at	 ﾠ national	 ﾠ and	 ﾠ
international	 ﾠ conferences.	 ﾠ All	 ﾠ of	 ﾠ which	 ﾠ may	 ﾠ attract	 ﾠ
postgraduate	 ﾠstudents,	 ﾠcompetitive	 ﾠgrants	 ﾠand	 ﾠlucrative	 ﾠ
collaborations.	 ﾠ In	 ﾠ Australia,	 ﾠf o r 	 ﾠe x a m p l e ,	 ﾠu n i v e r s i t i e s 	 ﾠ
who	 ﾠemploy	 ﾠacademics	 ﾠwho	 ﾠpublish	 ﾠon	 ﾠa	 ﾠpredetermined	 ﾠ
list	 ﾠof	 ﾠjournals	 ﾠare	 ﾠmore	 ﾠlikely	 ﾠto	 ﾠbe	 ﾠrewarded	 ﾠwith	 ﾠa	 ﾠ
larger	 ﾠshare	 ﾠof	 ﾠgovernment	 ﾠgrants	 ﾠand	 ﾠsubsidies.
20	 ﾠ
	 ﾠ
That	 ﾠis	 ﾠnot	 ﾠto	 ﾠsay	 ﾠthat	 ﾠpublication	 ﾠin	 ﾠthe	 ﾠhigh	 ﾠimpact	 ﾠ
journals	 ﾠmeans	 ﾠliving	 ﾠhappily	 ﾠever	 ﾠafter.	 ﾠThe	 ﾠreputation	 ﾠ
of	 ﾠ a	 ﾠ top	 ﾠ rated	 ﾠ medical	 ﾠ journal	 ﾠw a s 	 ﾠdamaged	 ﾠ by	 ﾠ a	 ﾠ
controversy	 ﾠ involving	 ﾠ its	 ﾠ response	 ﾠ to	 ﾠ problems	 ﾠ with	 ﾠ
research	 ﾠ on	 ﾠ a	 ﾠ drug	 ﾠ used	 ﾠ to	 ﾠ treat	 ﾠ pain.
21	 ﾠA 	 ﾠs t u d y 	 ﾠw a s 	 ﾠ
published	 ﾠin	 ﾠthe	 ﾠjournal	 ﾠin	 ﾠ2000	 ﾠwhich	 ﾠnoted	 ﾠan	 ﾠincrease	 ﾠ
in	 ﾠmyocardial	 ﾠinfarction	 ﾠamongst	 ﾠthose	 ﾠusing	 ﾠthe	 ﾠdrug.	 ﾠ
21	 ﾠ
Concerns	 ﾠabout	 ﾠthe	 ﾠrobustness	 ﾠof	 ﾠthat	 ﾠstudy	 ﾠwere	 ﾠraised	 ﾠ
with	 ﾠthe	 ﾠjournal	 ﾠin	 ﾠAugust	 ﾠ2001.	 ﾠAt	 ﾠthe	 ﾠsame	 ﾠtime	 ﾠboth	 ﾠ
the	 ﾠUS	 ﾠFood	 ﾠand	 ﾠDrug	 ﾠAdministration	 ﾠand	 ﾠanother	 ﾠmajor	 ﾠ
journal	 ﾠalso	 ﾠcast	 ﾠdoubt	 ﾠon	 ﾠthe	 ﾠinterpretation	 ﾠof	 ﾠthe	 ﾠdata	 ﾠ
that	 ﾠhad	 ﾠbeen	 ﾠpublished	 ﾠin	 ﾠthe	 ﾠjournal.	 ﾠ	 ﾠHowever	 ﾠit	 ﾠwas	 ﾠ
not	 ﾠuntil	 ﾠ2005	 ﾠthat	 ﾠthe	 ﾠjournal	 ﾠpublished	 ﾠconcern	 ﾠabout	 ﾠ
the	 ﾠoriginal	 ﾠstudy.	 ﾠDuring	 ﾠthat	 ﾠfive-ﾭ‐year	 ﾠperiod	 ﾠfunded	 ﾠ
reprints	 ﾠof	 ﾠthe	 ﾠoriginal	 ﾠarticle	 ﾠwere	 ﾠused	 ﾠto	 ﾠpromote	 ﾠthe	 ﾠ
offending	 ﾠdrug.	 ﾠ	 ﾠ
	 ﾠ
Publishing	 ﾠand	 ﾠprofit	 ﾠ
Most	 ﾠjournals	 ﾠare	 ﾠpeer	 ﾠreviewed	 ﾠby	 ﾠan	 ﾠunpaid	 ﾠarmy	 ﾠof	 ﾠ
academics	 ﾠand	 ﾠeditors.	 ﾠThe	 ﾠjournals	 ﾠmay	 ﾠthen	 ﾠbe	 ﾠsold	 ﾠto	 ﾠ
libraries.	 ﾠAn	 ﾠannual	 ﾠsubscription	 ﾠto	 ﾠsome	 ﾠjournals	 ﾠmay	 ﾠ
be	 ﾠ over	 ﾠ $20,000.	 ﾠ Publishers	 ﾠ make	 ﾠ substantial	 ﾠ profits.	 ﾠ
Here	 ﾠis	 ﾠa	 ﾠlist	 ﾠof	 ﾠpublished	 ﾠsubscription	 ﾠrates	 ﾠfor	 ﾠvarious	 ﾠ
top-ﾭ‐rated	 ﾠjournals:	 ﾠ
	 ﾠ
	 ﾠ
Journal	 ﾠ North	 ﾠ
American	 ﾠ
Institutional	 ﾠ
Subscription	 ﾠ
rate	 ﾠ in	 ﾠ $US	 ﾠ
(2010	 ﾠprices)	 ﾠ
Advertising	 ﾠ
cost	 ﾠ (full	 ﾠ
page	 ﾠ colour	 ﾠ
ad)	 ﾠ
Impact	 ﾠ
factor	 ﾠ
A	 ﾠ 1,232	 ﾠ 3825	 ﾠGBP	 ﾠ 30.76	 ﾠ
B	 ﾠ 625-ﾭ‐3740	 ﾠ 4822	 ﾠ(USD)	 ﾠ 23.5	 ﾠ
C	 ﾠ ‘Your	 ﾠ
institution,	 ﾠ
library,	 ﾠ or	 ﾠ
agency	 ﾠ is	 ﾠ a	 ﾠ
valuable	 ﾠ part	 ﾠ
of	 ﾠ our	 ﾠ
customer	 ﾠbase.	 ﾠ
Please	 ﾠ contact	 ﾠ
us	 ﾠ directly	 ﾠ for	 ﾠ
specific	 ﾠ pricing	 ﾠ
information’	 ﾠ
7136	 ﾠ(USD)	 ﾠ 17.5	 ﾠ
D	 ﾠ 1158	 ﾠ 1775	 ﾠGBP	 ﾠ 13.6	 ﾠ
E	 ﾠ 329	 ﾠ Please	 ﾠ
contact	 ﾠ a	 ﾠ
Sales	 ﾠ
Director	 ﾠ
47.05	 ﾠ
	 ﾠ
A	 ﾠ major	 ﾠ publisher	 ﾠ of	 ﾠ medical	 ﾠ journals	 ﾠ is	 ﾠ a	 ﾠg l o b a l 	 ﾠ
company	 ﾠ based	 ﾠ in	 ﾠ Amsterdam,	 ﾠ employing	 ﾠ more	 ﾠ
than	 ﾠ7,000	 ﾠpeople	 ﾠin	 ﾠ24	 ﾠcountries.	 ﾠIt	 ﾠclaims	 ﾠa	 ﾠglobal	 ﾠ
community	 ﾠof	 ﾠ7,000	 ﾠjournal	 ﾠeditors,	 ﾠ70,000	 ﾠeditorial	 ﾠ
board	 ﾠ members,	 ﾠ 300,000	 ﾠ reviewers	 ﾠ and	 ﾠ 600,000	 ﾠ
authors.	 ﾠ In	 ﾠ July	 ﾠ 2010	 ﾠthe	 ﾠcompany	 ﾠposted	 ﾠinterim	 ﾠ
profit	 ﾠresults	 ﾠwith	 ﾠa	 ﾠrevenue	 ﾠof	 ﾠalmost	 ﾠ3	 ﾠbillion	 ﾠGBP	 ﾠ
and	 ﾠ adjusted	 ﾠ profits	 ﾠ of	 ﾠ 758	 ﾠ million	 ﾠGBP	 ﾠin	 ﾠthe	 ﾠsix	 ﾠ
months	 ﾠending	 ﾠ30	 ﾠJune.
22	 ﾠThis	 ﾠis	 ﾠalso	 ﾠthe	 ﾠcompany	 ﾠ
that	 ﾠwas	 ﾠreported	 ﾠto	 ﾠhave	 ﾠbeen	 ﾠpaid	 ﾠan	 ﾠundisclosed	 ﾠ
sum	 ﾠ by	 ﾠ a	 ﾠ pharmaceutical	 ﾠ company	 ﾠ to	 ﾠ produce	 ﾠ
several	 ﾠvolumes	 ﾠof	 ﾠa	 ﾠpublication	 ﾠthat	 ﾠhad	 ﾠthe	 ﾠlook	 ﾠof	 ﾠ
a	 ﾠpeer-ﾭ‐reviewed	 ﾠmedical	 ﾠjournal,	 ﾠbut	 ﾠcontained	 ﾠonly	 ﾠ
reprinted	 ﾠ or	 ﾠ summarised	 ﾠ articles,	 ﾠ most	 ﾠ of	 ﾠ which	 ﾠ
presented	 ﾠdata	 ﾠfavourable	 ﾠto	 ﾠits	 ﾠproducts	 ﾠwith	 ﾠno	 ﾠ
disclosure	 ﾠof	 ﾠcompany	 ﾠsponsorship.
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Doctors	 ﾠand	 ﾠresearch	 ﾠ
Despite	 ﾠthe	 ﾠfact	 ﾠthat	 ﾠdoctors	 ﾠare	 ﾠkey	 ﾠto	 ﾠdelivering	 ﾠhealth	 ﾠ
care	 ﾠthey	 ﾠare	 ﾠseldom	 ﾠinvolved	 ﾠin	 ﾠresearch	 ﾠand	 ﾠfar	 ﾠless	 ﾠ
often	 ﾠc i t e d 	 ﾠ as	 ﾠ leaders	 ﾠ on	 ﾠ research	 ﾠ teams.	 ﾠ The	 ﾠ
relationship	 ﾠ between	 ﾠ the	 ﾠr e s e a r c h 	 ﾠo r g a n i s a t i o n s 	 ﾠa n d 	 ﾠ
doctors	 ﾠ is	 ﾠ the	 ﾠ key	 ﾠ to	 ﾠ understanding	 ﾠ their	 ﾠ limited	 ﾠ
involvement	 ﾠ in	 ﾠ innovation.	 ﾠ ‘Good’	 ﾠ research	 ﾠ is	 ﾠ a	 ﾠ
painstaking	 ﾠ science	 ﾠ in	 ﾠ which	 ﾠ clearly	 ﾠ defined	 ﾠ research	 ﾠ
questions	 ﾠ are	 ﾠ articulated,	 ﾠ appropriate	 ﾠ methods	 ﾠ are	 ﾠ
applied,	 ﾠ data	 ﾠ is	 ﾠ efficiently	 ﾠ collected	 ﾠ and	 ﾠ appropriate	 ﾠ
analysis	 ﾠis	 ﾠconducted	 ﾠto	 ﾠcraft	 ﾠconclusions	 ﾠthat	 ﾠtake	 ﾠinto	 ﾠ
account	 ﾠ the	 ﾠ limitations	 ﾠ and	 ﾠ strengths	 ﾠ of	 ﾠ the	 ﾠ study.	 ﾠ
Seldom,	 ﾠi f 	 ﾠe v e r ,	 ﾠd o e s 	 ﾠa 	 ﾠs i n g l e 	 ﾠs t u d y , 	 ﾠn o 	 ﾠm a t t e r 	 ﾠh o w 	 ﾠ
large,	 ﾠoffer	 ﾠrobust	 ﾠconclusions	 ﾠthat	 ﾠwill	 ﾠlead	 ﾠto	 ﾠchange	 ﾠin	 ﾠ
practice.	 ﾠ The	 ﾠ design	 ﾠ and	 ﾠ execution	 ﾠ of	 ﾠ high	 ﾠ quality	 ﾠ
research	 ﾠrequires	 ﾠexpertise	 ﾠwhich	 ﾠtakes	 ﾠmany	 ﾠyears	 ﾠof	 ﾠ
further	 ﾠtraining	 ﾠand	 ﾠexperience.	 ﾠThe	 ﾠacquisition	 ﾠof	 ﾠthese	 ﾠ
skills	 ﾠmay	 ﾠtake	 ﾠdoctors	 ﾠout	 ﾠof	 ﾠclinics	 ﾠand	 ﾠat	 ﾠa	 ﾠsignificant	 ﾠ
personal	 ﾠopportunity	 ﾠcost.	 ﾠ
	 ﾠ
The	 ﾠsubject	 ﾠof	 ﾠclinical	 ﾠresearch,	 ﾠi.e.	 ﾠpatients,	 ﾠmust	 ﾠgive	 ﾠ
informed	 ﾠ consent	 ﾠ before	 ﾠ they	 ﾠ can	 ﾠ be	 ﾠ included	 ﾠ in	 ﾠ a	 ﾠ
study.	 ﾠ This	 ﾠ is	 ﾠm o r e 	 ﾠc o m p l i c a t e d 	 ﾠt h a n 	 ﾠw o r k i n g 	 ﾠw i t h 	 ﾠ
uncomplaining	 ﾠrats	 ﾠin	 ﾠa	 ﾠsanitised	 ﾠlaboratory.	 ﾠIn	 ﾠpractice	 ﾠ	 ﾠ
limited	 ﾠcontrol	 ﾠover	 ﾠresearch	 ﾠsubjects	 ﾠmeans	 ﾠthat	 ﾠmost	 ﾠ
clinical	 ﾠresearch	 ﾠcannot	 ﾠbe	 ﾠgeneralised	 ﾠand	 ﾠis	 ﾠtherefore	 ﾠ
less	 ﾠlikely	 ﾠto	 ﾠbe	 ﾠpublished	 ﾠin	 ﾠhigh	 ﾠimpact	 ﾠjournals.	 ﾠMost	 ﾠ
research	 ﾠ is	 ﾠ also	 ﾠ conducted	 ﾠ at	 ﾠ universities,	 ﾠ directly	 ﾠ or	 ﾠ
indirectly.	 ﾠ Universities	 ﾠ and	 ﾠ medical	 ﾠ schools	 ﾠ have	 ﾠ to	 ﾠ
generate	 ﾠa	 ﾠsurplus	 ﾠincome	 ﾠto	 ﾠgrow	 ﾠin	 ﾠsize	 ﾠand	 ﾠinfluence.	 ﾠ
Very	 ﾠlittle	 ﾠresearch	 ﾠin	 ﾠprimary	 ﾠcare	 ﾠor	 ﾠpublic	 ﾠhealth	 ﾠhas	 ﾠa	 ﾠ
commercial	 ﾠ value,	 ﾠ therefore	 ﾠ to	 ﾠ profit	 ﾠ from	 ﾠ clinical	 ﾠ
research	 ﾠuniversities	 ﾠrely	 ﾠon	 ﾠgovernment	 ﾠf undi ng. 	 ﾠThe	 ﾠ
government	 ﾠ agenda	 ﾠ may	 ﾠ be	 ﾠ driven	 ﾠ by	 ﾠ political	 ﾠ
imperative.	 ﾠTherefore	 ﾠa	 ﾠgovernment	 ﾠminister	 ﾠunveiling	 ﾠ
shiny	 ﾠnew	 ﾠmachines	 ﾠmakes	 ﾠfor	 ﾠa	 ﾠfar	 ﾠmore	 ﾠvoter	 ﾠfriendly	 ﾠ
photo	 ﾠopportunity	 ﾠthan	 ﾠone	 ﾠlaunching	 ﾠa	 ﾠmore	 ﾠefficient	 ﾠ
way	 ﾠto	 ﾠrehabilitate	 ﾠpeople	 ﾠwith	 ﾠmental	 ﾠillness	 ﾠor	 ﾠmanage	 ﾠ
incontinence	 ﾠin	 ﾠgeneral	 ﾠpractice.	 ﾠ	 ﾠ
	 ﾠ
Therefore	 ﾠ funding	 ﾠ is	 ﾠ heavily	 ﾠ weighted	 ﾠ towards	 ﾠ
biomedical	 ﾠ sciences.	 ﾠ Here	 ﾠ the	 ﾠ focus	 ﾠ is	 ﾠ on	 ﾠ cure	 ﾠr a t h e r 	 ﾠ
than	 ﾠp r e v e n t i o n 	 ﾠo r 	 ﾠm o r e 	 ﾠe f f i c i e n t 	 ﾠs e r v i c e 	 ﾠd e l i v e r y .	 ﾠ
Genetic	 ﾠresearch,	 ﾠnano	 ﾠparticles	 ﾠand	 ﾠthe	 ﾠstudy	 ﾠof	 ﾠprions,	 ﾠ
is	 ﾠtherefore	 ﾠmore	 ﾠlikely	 ﾠto	 ﾠget	 ﾠgenerously	 ﾠfunded	 ﾠthan	 ﾠ
research	 ﾠon	 ﾠsystem	 ﾠdesign	 ﾠthat	 ﾠwould	 ﾠallow	 ﾠpeople	 ﾠto	 ﾠ
die	 ﾠin	 ﾠcomfort	 ﾠin	 ﾠtheir	 ﾠown	 ﾠhomes.	 ﾠ	 ﾠ
	 ﾠ
In	 ﾠ2010	 ﾠthe	 ﾠAustralian	 ﾠNational	 ﾠHealth	 ﾠand	 ﾠMedical	 ﾠ
Research	 ﾠCouncil	 ﾠdivided	 ﾠits	 ﾠresearch	 ﾠfunding	 ﾠso	 ﾠthat	 ﾠ
39%	 ﾠ of	 ﾠ the	 ﾠ funds	 ﾠ were	 ﾠ awarded	 ﾠ to	 ﾠ preventive	 ﾠ
medicine	 ﾠand	 ﾠpublic	 ﾠhealth.	 ﾠAt	 ﾠthe	 ﾠsame	 ﾠtime	 ﾠthe	 ﾠ
majority	 ﾠ of	 ﾠ government	 ﾠ funding	 ﾠ on	 ﾠ health	 ﾠ care	 ﾠ in	 ﾠ
practice	 ﾠis	 ﾠon	 ﾠso-ﾭ‐called	 ﾠprimary	 ﾠcare	 ﾠservices.
24	 ﾠFor	 ﾠ
universities	 ﾠ the	 ﾠ return	 ﾠ on	 ﾠ investment	 ﾠ does	 ﾠ not	 ﾠ
favour	 ﾠ clinical	 ﾠ research,	 ﾠ so	 ﾠ that	 ﾠ laboratory-ﾭ‐based	 ﾠ
research	 ﾠ on	 ﾠa 	 ﾠc u r e 	 ﾠf o r 	 ﾠc a n c e r 	 ﾠm a k e s 	 ﾠa 	 ﾠf a r 	 ﾠm o r e 	 ﾠ
compelling	 ﾠcase	 ﾠthan	 ﾠresearch	 ﾠinvolving	 ﾠtherapists	 ﾠin	 ﾠ
the	 ﾠ community	 ﾠ or	 ﾠ models	 ﾠ of	 ﾠ disease	 ﾠ self-ﾭ‐
management.	 ﾠ And	 ﾠ yet,	 ﾠ in	 ﾠ the	 ﾠ scheme	 ﾠ of	 ﾠ things,	 ﾠ
research	 ﾠ in	 ﾠ how	 ﾠ to	 ﾠ deliver	 ﾠ an	 ﾠ equitable	 ﾠ health	 ﾠ
service	 ﾠis	 ﾠgoing	 ﾠto	 ﾠmake	 ﾠmore	 ﾠof	 ﾠan	 ﾠimpression	 ﾠon	 ﾠ
the	 ﾠcommunity	 ﾠin	 ﾠthe	 ﾠshort	 ﾠterm	 ﾠthan	 ﾠresearch	 ﾠon	 ﾠa	 ﾠ
cure	 ﾠfor	 ﾠcancer	 ﾠthat	 ﾠmay	 ﾠbe	 ﾠ20	 ﾠyears	 ﾠaway.	 ﾠ	 ﾠ
	 ﾠ
Academics	 ﾠ understand	 ﾠ that	 ﾠ universities	 ﾠ are	 ﾠ
financially	 ﾠrewarded	 ﾠfor	 ﾠadopting	 ﾠthis	 ﾠparadigm	 ﾠby	 ﾠa	 ﾠ
system	 ﾠthat	 ﾠis	 ﾠdriven	 ﾠby	 ﾠpriorities	 ﾠrelated	 ﾠto	 ﾠa	 ﾠreturn	 ﾠ
on	 ﾠ investment.	 ﾠ Given	 ﾠ the	 ﾠ competitive	 ﾠ nature	 ﾠ of	 ﾠ
those	 ﾠ who	 ﾠ enrol	 ﾠ in	 ﾠ medical	 ﾠ school	 ﾠ this	 ﾠ is	 ﾠ a	 ﾠ
considerable	 ﾠdisincentive	 ﾠand	 ﾠdrives	 ﾠclinicians	 ﾠout	 ﾠof	 ﾠ
research.	 ﾠAs	 ﾠif	 ﾠthat	 ﾠwas	 ﾠnot	 ﾠsufficient	 ﾠdisincentive,	 ﾠ
there	 ﾠare	 ﾠmajor	 ﾠchallenges	 ﾠto	 ﾠrecruiting	 ﾠparticipants	 ﾠ
in	 ﾠclinical	 ﾠpractice.
25	 ﾠPatients	 ﾠdo	 ﾠnot	 ﾠseek	 ﾠhelp	 ﾠfrom	 ﾠ
doctors	 ﾠ only	 ﾠ to	 ﾠ spend	 ﾠ most	 ﾠ of	 ﾠ their	 ﾠ consultation	 ﾠ
negotiating	 ﾠan	 ﾠopportunity	 ﾠto	 ﾠparticipate	 ﾠin	 ﾠresearch	 ﾠ
that	 ﾠmay	 ﾠor	 ﾠmay	 ﾠnot	 ﾠbenefit	 ﾠthem	 ﾠdirectly.	 ﾠWhen	 ﾠ
the	 ﾠpatient	 ﾠis	 ﾠpaying	 ﾠfor	 ﾠthe	 ﾠdoctor’s	 ﾠtime,	 ﾠas	 ﾠis	 ﾠthe	 ﾠ
case	 ﾠin	 ﾠmany	 ﾠcountries,	 ﾠdoctors	 ﾠhave	 ﾠno	 ﾠincentive	 ﾠto	 ﾠ
introduce	 ﾠdistractions	 ﾠto	 ﾠthat	 ﾠconsultation.	 ﾠIn	 ﾠreality	 ﾠ
many	 ﾠof	 ﾠthe	 ﾠpatients	 ﾠin	 ﾠclinical	 ﾠpractice	 ﾠare	 ﾠexcluded	 ﾠ
from	 ﾠresearch	 ﾠdesigns	 ﾠwhich	 ﾠusually	 ﾠfavour	 ﾠyoung,	 ﾠ
articulate,	 ﾠ English	 ﾠ speaking,	 ﾠ literate,	 ﾠ relatively	 ﾠ
healthy	 ﾠ people	 ﾠ and	 ﾠ not	 ﾠ those	 ﾠl i v i n g 	 ﾠw i t h 	 ﾠt h e 	 ﾠ
conditions	 ﾠf o r 	 ﾠw h o m 	 ﾠt h e 	 ﾠe v i d e n c e 	 ﾠh a s 	 ﾠa p p a r e n t l y 	 ﾠ
been	 ﾠgenerated.
26	 ﾠ
	 ﾠ
Conclusions	 ﾠ
Doctors	 ﾠ are	 ﾠ not	 ﾠ generally	 ﾠ actively	 ﾠ involved	 ﾠ in	 ﾠ
research,	 ﾠthey	 ﾠmay	 ﾠnot	 ﾠcritically	 ﾠappraise	 ﾠresearch	 ﾠ
articles	 ﾠand	 ﾠtheir	 ﾠknowledge	 ﾠof	 ﾠrecent	 ﾠadvances	 ﾠin	 ﾠ
their	 ﾠfield	 ﾠmay	 ﾠbe	 ﾠout	 ﾠof	 ﾠdate.	 ﾠFor	 ﾠexample	 ﾠthere	 ﾠare	 ﾠ
cases	 ﾠof	 ﾠdoctors	 ﾠcontinuing	 ﾠto	 ﾠprescribe	 ﾠdrugs	 ﾠthat	 ﾠ
have	 ﾠbeen	 ﾠreported	 ﾠto	 ﾠcause	 ﾠharm.	 ﾠA	 ﾠvast	 ﾠnumber	 ﾠof	 ﾠ
research	 ﾠpapers	 ﾠare	 ﾠpublished	 ﾠevery	 ﾠyear	 ﾠand	 ﾠmost	 ﾠ
of	 ﾠthese	 ﾠhave	 ﾠsignificant	 ﾠlimitations	 ﾠand	 ﾠsome	 ﾠpoor	 ﾠ	 ﾠAustralasian	 ﾠMedical	 ﾠJournal	 ﾠ[AMJ	 ﾠ2012,	 ﾠ5,	 ﾠ8,	 ﾠ462-ﾭ‐467]	 ﾠ
	 ﾠ
	 ﾠ
466	 ﾠ
science	 ﾠmay	 ﾠeven	 ﾠbe	 ﾠpublished	 ﾠin	 ﾠthe	 ﾠmost	 ﾠinfluential	 ﾠ
journals.	 ﾠ Publishers	 ﾠ and	 ﾠ manufacturers	 ﾠ of	 ﾠ
pharmaceuticals	 ﾠhave	 ﾠsometimes	 ﾠcolluded	 ﾠin	 ﾠways	 ﾠthat	 ﾠ
do	 ﾠ not	 ﾠ necessarily	 ﾠ benefit	 ﾠ patients.	 ﾠ 	 ﾠ The	 ﾠ need	 ﾠ for	 ﾠ
specialist	 ﾠ research	 ﾠ skills	 ﾠ as	 ﾠ well	 ﾠ as	 ﾠ research	 ﾠ funding	 ﾠ
structures	 ﾠmean	 ﾠthat	 ﾠthose	 ﾠmost	 ﾠclosely	 ﾠinvolved	 ﾠwith	 ﾠ
patients	 ﾠ neither	 ﾠ lead	 ﾠ research	 ﾠ nor	 ﾠ participate	 ﾠi n 	 ﾠ
research	 ﾠprojects.	 ﾠMuch	 ﾠof	 ﾠthe	 ﾠmost	 ﾠgenerously	 ﾠfunded	 ﾠ
research	 ﾠis	 ﾠaimed	 ﾠat	 ﾠlong-ﾭ‐term	 ﾠcommercial	 ﾠgoals	 ﾠrather	 ﾠ
than	 ﾠto	 ﾠbenefit	 ﾠpatients.	 ﾠ
	 ﾠ
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